New Developments in the Pathogenesis of Preeclampsia

Advances in Chronic Kidney Disease

Volumn 20, Issue 3, 2013, Pages 265-270

  Naljayan, Mihran V ^a   Karumanchi, S Ananth ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Angiogenesis; Cardiovascular disease; Preeclampsia; Proteinuria

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RELAXIN;

CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MATERNAL MORBIDITY; MATERNAL MORTALITY; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PERINATAL MORBIDITY; PERINATAL MORTALITY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; THIRD TRIMESTER PREGNANCY; TREATMENT PLANNING;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84876871998     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.02.003     Document Type: Review

References (83)

1. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365(9461):785-799.
2. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000, 183(1):S1-S22.
3. Young B.C., Levine R.J., Karumanchi S.A. Pathogenesis of preeclampsia. Annu Rev Pathol 2010, 5:173-192.
4. Mattar F., Sibai B.M. Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 2000, 182(2):307-312.
5. MacKay A.P., Berg C.J., Atrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001, 97(4):533-538.
6. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011, 123(24):2856-2869.
7. Barton J.R., Sibai B.M. Prediction and prevention of recurrent preeclampsia. Obstetrics Gynecol 2008, 112:359-372.
8. Khong T.Y., De Wolf F., Robertson W.B., Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986, 93(1):1049-1059.
9. Zhou Y., Damsky C.H., Fisher S.J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J Clin Invest 1997, 99(9):2152-2164.
10. Cudmore M., Ahmad S., Al-Ani B., et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007, 115(13):1789-1797.
11. Cui Y., Wang W., Dong N., et al. Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature 2012, 484(7393):246-250.
12. Hiby S.E., Walker J.J., O'Shaughnessy K.M., et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004, 200(8):957-965.
13. Kanasaki K., Palmsten K., Sugimoto H., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008, 453:1117-1121.
14. Zhou A., Carrell R.W., Murphy M.P., et al. A redox switch in angiotensinogen modulates angiotensin release. Nature 2010, 468:108-111.
15. Zhou C.C., Zhang Y., Irani R.A., et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008, 14(8):855-862.
16. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308(5728):1592-1594.
17. Karumanchi S.A., Maynard S.E., Stillman I.E., Epstein F.H., Sukhatme V.P. Preeclampsia: a renal perspective. Kidney Int 2005, 67(6):2101-2113.
18. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 2004, 95(9):884-891.
19. Chaiworapongsa T., Romero R., Espinoza J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004, 190(6):1541-1547. discussion 7-50.
20. Chaiworapongsa T., Romero R., Kim Y.M., et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005, 17(1):3-18.
21. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005.
22. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. New Engl J Med 2004, 350(10):672-683.
23. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658.
24. Noori M., Donald A.E., Angelakopoulou A., Hingorani A.D., Williams D.J. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010, 122(5):478-487.
25. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12(6):642-649.
26. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003, 111(5):707-716.
27. Lafayette R.A., Druzin M., Sibley R., et al. Nature of glomerular dysfunction in pre-eclampsia. Kidney Int 1998, 54(4):1240-1249.
28. Maharaj A.S., Walshe T.E., Saint-Geniez M., et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008, 205(2):491-501.
29. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. New Engl J Med 2008, 358(11):1129-1136.
30. Glusker P., Recht L., Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354(9):980-982. discussion 980-982.
31. Ozcan C., Wong S.J., Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354(9):980-982. discussion 980-982.
32. Patel T.V., Morgan J.A., Demetri G.D., et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008, 100(4):282-284.
33. Li F., Hagaman J.R., Kim H.S., et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol 2012, 23(4):652-660.
34. Sela S., Itin A., Natanson-Yaron S., et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008, 102(12):1566-1574.
35. Rajakumar A., Cerdeira A.S., Rana S., et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 2012, 59(2):256-264.
36. Tsatsaris V., Goffin F., Munaut C., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003, 88(11):5555-5563.
37. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004, 89(2):770-775.
38. Romero R., Nien J.K., Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008, 21(1):9-23.
39. Silasi M., Rana S., Powe C., et al. Placental expression of angiogenic factors in Trisomy 13. Am J Obstet Gynecol 2011, 204(6):546.e1-546.e4.
40. Mijal R.S., Holzman C.B., Rana S., Karumanchi S.A., Wang J., Sikorskii A. Mid-pregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011, 204(3):244.e1-244.e12.
41. Kanter D., Lindheimer M.D., Wang E., et al. Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol 2010, 202(2):184.e1-184.e5.
42. Faupel-Badger J.M., Wang Y., Karumanchi S.A., et al. Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes Control 2011, 22(11):1587-1595.
43. Bdolah Y., Lam C., Rajakumar A., et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?. Am J Obstet Gynecol 2008, 198(4):428.e1-428.e6.
44. Signore C., Mills J.L., Qian C., et al. Circulating angiogenic factors and placental abruption. Obstet Gynecol 2006, 108(2):338-344.
45. Signore C., Mills J.L., Qian C., et al. Circulating soluble endoglin and placental abruption. Prenat Diagn 2008, 28(9):852-858.
46. Vaisbuch E., Whitty J., Hassan S., et al. Circulating angiogenic and anti-angiogenic factors in women with eclampsia. Am J Obstet Gynecol 2011, 204(2):152.e1-152.e9.
47. Buhimschi C.S., Norwitz E.R., Funai E., et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 2005, 192(3):734-741.
48. Qazi U., Lam C., Karumanchi S.A., Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 2008, 35(4):631-634.
49. Rolfo A., Attini R., Nuzzo A.M., et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013, 83(1):177-181.
50. Salahuddin S., Lee Y., Vadnais M., Sachs B.P., Karumanchi S.A., Lim K.H. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007, 197(1):28.e1-28.e6.
51. Sunderji S., Gaziano E., Wothe D., et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010, 202(1):40.e1-40.e7.
52. Verlohren S., Galindo A., Schlembach D., et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010, 202(2):161.e1-161.e11.
53. Verlohren S., Herraiz I., Lapaire O., et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012, 206(1):58.e1-58.e8.
54. Young B., Levine R.J., Salahuddin S., et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010, 23(5):366-370.
55. Levine R.J., Thadhani R., Qian C., et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005, 293(1):77-85.
56. Perni U., Sison C., Sharma V., et al. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012, 59(3):740-746.
57. Rana S., Powe C.E., Salahuddin S., et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012, 125(7):911-919.
58. Chaiworapongsa T., Romero R., Savasan Z.A., et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011, 24(10):1187-1207.
59. Moore A.G., Young H., Keller J.M., et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012, 25(12):2651-2657.
60. Sibiude J., Guibourdenche J., Dionne M.D., et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012, 7(11):e50208.
61. Rana S., Cerdeira A.S., Wenger J., et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 2012, 7(10):e48259.
62. Powers R.W., Roberts J.M., Plymire D.A., et al. Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?. Hypertension 2012, 60(1):239-246.
63. Gilbert J.S., Verzwyvelt J., Colson D., Arany M., Karumanchi S.A., Granger J.P. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 2010, 55(2):380-385.
64. Li Z., Zhang Y., Ying Ma J., et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007, 50(4):686-692.
65. Suzuki H., Ohkuchi A., Matsubara S., et al. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009, 54(5):1129-1135.
66. Kumasawa K., Ikawa M., Kidoya H., et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011, 108(4):1451-1455.
67. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res 2011, 127(Suppl 3):S72-S75.
68. Thadhani R., Kisner T., Hagmann H., et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011, 124(8):940-950.
69. McGuane J.T., Danielson L.A., Debrah J.E., Rubin J.P., Novak J., Conrad K.P. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 2011, 57(6):1151-1160.
70. Unemori E., Sibai B., Teichman S.L. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann N Y Acad Sci 2009, 1160:381-384.
71. Funai E.F., Friedlander Y., Paltiel O., et al. Long-term mortality after preeclampsia. Epidemiology 2005, 16(2):206-215.
72. Irgens H.U., Reisaeter L., Irgens L.M., Lie R.T. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001, 323(7323):1213-1217.
73. Ray J.G., Vermeulen M.J., Schull M.J., Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005, 366(9499):1797-1803.
74. Mongraw-Chaffin M.L., Cirillo P.M., Cohn B.A. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension 2010, 56(1):166-171.
75. Romundstad P.R., Magnussen E.B., Smith G.D., Vatten L.J. Hypertension in pregnancy and later cardiovascular risk. Common antecedents?. Circulation 2010, 122(6):579-584.
76. Saxena A.R., Karumanchi S.A., Brown N.J., Royle C.M., McElrath T.F., Seely E.W. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension 2010, 55(5):1239-1245.
77. Wolf M., Hubel C.A., Lam C., et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004, 89(12):6239-6243.
78. Patten I.S., Rana S., Shahul S., et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012, 485(7398):333-338.
79. Jayet P.Y., Rimoldi S.F., Stuber T., et al. Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. Circulation 2010, 122(5):488-494.
80. Vikse B.E., Irgens L.M., Leivestad T., Skjaerven R., Iversen B.M. Preeclampsia and the risk of end-stage renal disease. New Engl J Med 2008, 359(8):800-809.
81. Wang I.K., Muo C.H., Chang Y.C., et al. Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study. CMAJ 2013, 185(3):207-213.
82. McDonald S.D., Han Z., Walsh M.W., Gerstein H.C., Devereaux P.J. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis 2010, 55(6):1026-1039.
83. Vikse B.E., Irgens L.M., Karumanchi S.A., Thadhani R., Reisaeter A.V., Skjaerven R. Familial factors in the association between preeclampsia and later ESRD. Clin J Am Soc Nephrol 2012, 7(11):1819-1826.